skip to main content

Diabetic kidney disease — RACGP Fellowship MCQ

Instant feedback + full explanation. One question, done properly.

HardChronic disease managementDiabetic kidney diseaseRACGP Fellowship

A 64‑year‑old man with type 2 diabetes attends review. HbA1c is 63 mmol/mol, eGFR 42 mL/min/1.73 m² and urine ACR 42 mg/mmol on repeat testing. Blood pressure is 146/86 mmHg despite perindopril 5 mg daily. He has ankle oedema but no dyspnoea. What is the most appropriate management?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: DOptimise ACE inhibitor dose if tolerated, add an SGLT2 inhibitor if appropriate and monitor renal function

Explanation lettering: D = shown as A · C = shown as B · A = shown as C · E = shown as D · B = shown as E

Option E is correct. RACGP guidelines advise continuing and uptitrating ACE inhibition in diabetic patients with albuminuria, plus adding an SGLT2 inhibitor for kidney and cardiovascular protection (eGFR ≥20 mL/min/1.73 m² and albuminuria) ([racgp.org.au](https://www.racgp.org.au/getattachment/00186565-b7b3-4eb8-aefb-e7f8ff3973d5/Management-of-type-2-diabetes-A-handbook-for-general-practice.aspx?utm_source=openai)). Discontinuing ACE inhibition (A) is harmful; loop diuretic alone (B) manages symptoms but offers no disease-modifying renal benefit; dialysis education (C) is premature at eGFR 42; and dietary sugar restriction alone (D) is insufficient without pharmacologic intervention.

Reference: RACGP Management of type 2 diabetes: A handbook for general practice (2024 edition), Summary of recommendations; RACGP Type 2 diabetes guideline – chronic kidney disease recommendations (2024) – both above URLs, https://www.racgp.org.au/getattachment/00186565-b7b3-4eb8-aefb-e7f8ff3973d5/Management-of-type-2-diabetes-A-handbook-for-general-practice.aspx